Register for email alerts and news feeds:
This journal | BMJ Group
rss
Archives of Disease in Childhood 1998;79:323-327; doi:10.1136/adc.79.4.323
Copyright © 1998 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health.
Arch Dis Child 1998;79:323-327 ( October )

Efficacy of Zoladex LA (goserelin) in the treatment of girls with central precocious or early puberty

W F Paterson,a E McNeill,a S Reid,b A S Hollman,b M D C Donaldsona

a Department of Child Health, Royal Hospital for Sick Children, Yorkhill, Glasgow G3 8SJ, UK, b Department of Diagnostic Imaging, Royal Hospital for Sick Children

Correspondence to: Dr Donaldson.


Accepted 12 May 1998

OBJECTIVE---To assess the efficacy of a longer acting preparation of the gonadotrophin releasing hormone (GnRH) analogue goserelin (Zoladex LA, 10.8 mg) in 12 girls with central precocious or early puberty.
METHODS---Two girls started treatment de novo; the remainder had been on suppressive treatment for a median duration of 1.5 (range, 0.2-5.6) years. Assessment comprising auxology, pubertal staging, and pelvic ultrasound examination was carried out at weeks 0, 4, 8, 10, and 12 (first cycle) and weeks 8, 10, and 12 (second cycle) to evaluate the required injection frequency. Thereafter, assessment was performed on the day of injection. Zoladex LA was given every 12 weeks unless pubertal progression occurred.
RESULTS---Satisfactory control was achieved in eight patients using this regimen, and three patients required more frequent injections. One girl was removed from the study because of clinical progression and extreme mood swings. No serious adverse effects occurred. Mean height velocity during the study period was 4.5 cm/year (range, 3.1-6.6) compared with 6.5 cm/year (range, 3.8-9.6) before treatment in nine patients for whom data were available.
CONCLUSIONS---Zoladex LA was effective in controlling precocious puberty in girls when given at intervals of 9-12 weeks and it is recommended that an initial assessment is made eight weeks after beginning treatment.

Keywords: central precocious puberty; gonadotrophin releasing hormone analogue treatment; height velocity


© 1998 by Archives of Disease in Childhood

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • O'Sullivan, E, O'Sullivan, M, Mann, N (2002). Precocious puberty: a parent's perspective. Arch. Dis. Child. 86: 320-321 [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Latest from ADC

 

ADC is co-owned by the RCPCH and is the official journal of the European Academy of Paediatrics

BMJ Careers - Latest Paediatrics and Paediatric Surgery Jobs

Paediatrics and Paediatric Surgery Jobs